Splitomicin

SKU: orb1300563

Description

Splitomicin is a specific Sir2p (NAD+-dependent histone deacetylase) inhibitor with an IC50 of 60 µM. This cell-active small molecule is a valuable research tool for studying chromatin biology, epigenetic regulation, and aging-related pathways in both in vitro and in vivo experimental models.

Research Area

Epigenetics & Chromatin

Key Properties

• CAS Number: 5690-03-9
• MW: 198.22
• Purity: >98%
• Formula: C₁₃H₁₀O₂
• SMILES: O=C1CCc2c(O1)ccc1ccccc21
• Target: Protein deacetylase
• Solubility: Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 25 mg/ml).

Bioactivity

• Target IC50:
  Sir2p:60 μM
• In Vivo:
  In a photochemical injury mouse model, splitomicin (80 mg/kg/d i.p.) enhances tissue factor activity in the arterial vessel wall and promotes carotid artery thrombus formation.
  Read more...
• In Vitro:
  Splitomicin inhibits Sir2p deacetylase activity by altering or blocking access to the acetylated histone binding pocket. Splitomicin inhibits platelet aggregation induced by thrombin, collagen, AA and U46619 via inhibition of cyclic AMP phosphodiesterase activity and subsequent inhibition of intracellular Ca(++) mobilization, TXB2 formation and ATP release.
  Read more...

Storage & Handling

• Storage: RT
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Splitomycin

Compound Identifiers

PubChem CID

5269